Amgen paying $71 million for misleading promotion of drugs

August 20, 2015 5:37 AM

18 0

Amgen paying $71 million for misleading promotion of drugs

California-based drugmaker Amgen has agreed to pay $71 million to 48 states, including Pennsylvania, New Jersey and Delaware, and the District of Columbia, to settle allegations that it violated consumer protection laws with misleading promotion of the anemia drug Aranesp and the plaque psoriasis drug Enbrel.

Pennsylvania is likely to get about $2.4 million of the total, accoring to the Attorney General's Office. The New Jersey Attorney General's Office said that state would get about $1.57 million.

Also read: 1 Officer Dead, 1 Critically Injured After Shooting Near Georgia Southwestern State University

Read more

To category page

Loading...